Enveric Biosciences Inc (ENVB) Stock Price, Quote & News

Company Profile

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. The company offers product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. It also focuses on the development of cannabinoid conjugate molecules...

Industry: Biotechnology

Sector: Healthcare

Website: www.enveric.com

Address:

245 First Street, Riverview II 18 th Floor, Cambridge, United States

Lakeland_73 Feb. 23 at 5:57 PM

$ENVB Pathetic volume. Worse price

0 · Reply

EmC_Invests Feb. 23 at 1:25 PM

$ENVB biotech microcap under the radar if buyers return this can move quickly

0 · Reply

__ChartMenace Feb. 23 at 12:41 PM

$ABP $NCEL $NVA $ENVB 6

0 · Reply

HarrisMargin Feb. 23 at 5:35 AM

$ENVB microcap biotech compressing quietly if buyers appear squeeze risk rises

0 · Reply

UgoGreg Feb. 22 at 9:18 PM

$ENVB https://youtu.be/nCPt9XhiRxk

0 · Reply

UgoGreg Feb. 22 at 5:46 PM

$ENVB https://youtu.be/VcWJkTGHJVM

0 · Reply

Luckyjs38 Feb. 21 at 5:02 PM

$ENVB

0 · Reply

Luckyjs38 Feb. 21 at 5:01 PM

$ENVB

0 · Reply

PurplePineApples Feb. 21 at 2:08 AM

$ENVB forming the base let’s see if we can reclaim the 2.30s

0 · Reply

Lakeland_73 Feb. 20 at 9:48 PM

$ENVB 15,000 watchers and 4 posts all day about this trash.

1 · Reply

Enveric Biosciences Reports EB-003 BRET Receptor Engagement Assay Data

Jan 29, 2026, 8:00 AM EST - 25 days ago

Enveric Biosciences Expands Collaboration with TOTEC Pharma through Trademark License and Option

Jan 28, 2026, 5:00 PM EST - 26 days ago

Enveric Biosciences Announces Closing of $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Jan 28, 2026, 8:00 AM EST - 26 days ago

Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Dec 29, 2025, 8:00 AM EST - 2 months ago

Enveric Biosciences Announces Patent Issuance

Dec 12, 2025, 4:46 PM EST - 2 months ago

Enveric Biosciences Announces Closing of Exercise of Warrants for $3.1 Million Gross Proceeds

Dec 11, 2025, 1:43 PM EST - 2 months ago

Enveric Biosciences Announces Exercise of Warrants for $3.1 Million Gross Proceeds

Dec 9, 2025, 8:00 AM EST - 2 months ago

Enveric Biosciences Receives Notice of Allowance for EVM301 Series of Drug Candidates

Dec 4, 2025, 8:00 AM EST - 2 months ago

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 9th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2026”

Nov 26, 2025, 8:00 AM EST - 3 months ago

Enveric Biosciences Receives Fourth Notice of Allowance for EVM401 Series of Drug Candidates

Nov 14, 2025, 4:05 PM EST - 3 months ago

Enveric Biosciences Reports Third Quarter 2025 Financial and Corporate Results

Oct 23, 2025, 8:00 AM EDT - 4 months ago

Enveric Biosciences Announces Reverse Stock Split

Oct 16, 2025, 8:30 AM EDT - 4 months ago

Enveric Biosciences Further Enhances Intellectual Property Estate with New U.S. Patent Issuance

Oct 15, 2025, 8:00 AM EDT - 4 months ago

Enveric Biosciences Hires IP Powerhouse to Defend Its U.S. Patent with Claims Relevant to Bretisilocin, Recently Acquired by AbbVie in $1.2 Billion Deal

Oct 14, 2025, 9:00 AM EDT - 4 months ago

Enveric Biosciences to Explore Digital Asset Treasury Opportunities

Oct 2, 2025, 8:45 AM EDT - 5 months ago

Enveric Biosciences Successfully Completes Key Manufacturing Milestones in Support of Planned IND and Clinical Trials

Sep 18, 2025, 4:30 PM EDT - 5 months ago

Enveric Biosciences Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Sep 17, 2025, 9:24 AM EDT - 5 months ago

Enveric Biosciences Announces Exercise of Warrants for $2.2 Million Gross Proceeds

Sep 17, 2025, 8:00 AM EDT - 5 months ago

Enveric Biosciences Announces Publication of Two Peer-Reviewed Articles Highlighting Novel Bioproduction Methods for Neuropsychiatric Drug Discovery

Sep 16, 2025, 8:45 AM EDT - 5 months ago

Enveric Biosciences Receives FDA Response and Streamlines Plans for EB-003 IND Submission

Sep 3, 2025, 8:30 AM EDT - 6 months ago

Enveric Biosciences to Present at H.C. Wainwright 27th Annual Global Investment Conference

Sep 2, 2025, 8:30 AM EDT - 6 months ago

Enveric Biosciences Relocates Corporate Headquarters to Cambridge, MA

Aug 28, 2025, 8:30 AM EDT - 6 months ago

Enveric Biosciences Successfully Completes Pre-IND Dose Range Finding Studies for Lead Candidate EB-003, Targeting Neuropsychiatric Indications

Aug 14, 2025, 8:00 AM EDT - 6 months ago

Enveric Biosciences Reports Second Quarter 2025 Financial and Corporate Results

Jul 23, 2025, 8:03 AM EDT - 7 months ago

Enveric Biosciences Secures Second U.S. Patent Allowance for Next-Generation, Non-Hallucinogenic Mescaline Derivatives in EVM401 Series

Jul 15, 2025, 9:03 AM EDT - 7 months ago

Enveric Biosciences Lead Drug Candidate EB-003 Demonstrates Positive Effects in Preclinical Model of Post-Traumatic Stress Disorder (PTSD)

Jun 24, 2025, 9:03 AM EDT - 8 months ago

Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003

Jun 16, 2025, 10:46 AM EDT - 9 months ago

Enveric Biosciences Announces Participation in 2025 BIO International Convention

Jun 10, 2025, 9:03 AM EDT - 9 months ago

Enveric Biosciences Receives Notice of Allowance for New Class of Low-Hallucinogenic Neuroplastogens Targeting Psychiatric Disorders

Jun 3, 2025, 9:00 AM EDT - 9 months ago

Enveric Biosciences Announces Issuance of U.S. Patent Covering a Novel Family of Molecules Including Melatonin Receptor-Targeting Compounds

May 28, 2025, 9:03 AM EDT - 9 months ago

Enveric Biosciences Reports Positive Preclinical Results for Lead Drug Candidate EB-003

May 20, 2025, 8:00 AM EDT - 9 months ago

Enveric Biosciences Identifies Neuroplastogen Candidates with Potential to Address Neurodegenerative Disease

May 14, 2025, 4:15 PM EDT - 10 months ago

Enveric Biosciences Reports First Quarter 2025 Financial and Corporate Results

Mar 31, 2025, 8:00 AM EDT - 11 months ago

Enveric Biosciences Reports Financial Results and Provides Corporate Update for Fourth Quarter and Fiscal Year Ended 2024

Mar 17, 2025, 1:40 PM EDT - 1 year ago

Enveric Biosciences Participating in BIO-Europe Spring®

Mar 6, 2025, 10:00 AM EST - 1 year ago

Enveric Biosciences Launches Request-For-Proposals Solicitation Process for PsyAI Trademark

Feb 27, 2025, 9:30 AM EST - 1 year ago

Enveric Biosciences CEO Issues Letter to Shareholders

Feb 25, 2025, 1:30 PM EST - 1 year ago

Enveric Biosciences Unveils EVM401 Series of Compounds with New U.S. Patent

Feb 4, 2025, 8:00 AM EST - 1 year ago

Enveric Biosciences and Restoration Biologics Announce Licensing Agreements to Treat Joint Disease

Feb 3, 2025, 5:00 PM EST - 1 year ago

Enveric Biosciences Announces Closing of $5 Million Public Offering

Jan 30, 2025, 8:14 PM EST - 1 year ago

Enveric Biosciences Announces Pricing of $5 Million Public Offering

Jan 30, 2025, 4:01 PM EST - 1 year ago

Enveric Biosciences Receives Notice of Allowance for Lead Drug Candidate EB-003 from United States Patent and Trademark Office

Jan 6, 2025, 8:30 AM EST - 1 year ago

Enveric Biosciences to Present at and Participate in Panel Discussion at Sachs Associates 8th Annual Neuroscience Innovation Forum During “J.P. Morgan Week 2025”

Dec 2, 2024, 8:00 AM EST - 1 year ago

Enveric Biosciences Announces New U.S. Patents Supporting EVM301 Series and EVM201 Series Compounds

Nov 25, 2024, 9:00 AM EST - 1 year ago

Enveric Biosciences Preclinical Pharmacokinetic Studies of EB-003 Support Oral Bioavailability, Demonstrate Brain Penetration, and Show No Evidence of Hallucination-like Behavior

Nov 14, 2024, 4:05 PM EST - 1 year ago

Enveric Biosciences Reports Third Quarter 2024 Financial and Corporate Results

Nov 12, 2024, 9:00 AM EST - 1 year ago

Enveric Biosciences Signs Out-Licensing Agreement with MycoMedica Life Sciences for EB-002

Nov 4, 2024, 10:36 AM EST - 1 year ago

Enveric Biosciences Announces Broad Range of Patent Issuances

Oct 15, 2024, 8:00 AM EDT - 1 year ago

Enveric Biosciences Announces Positive Pharmacology and Safety Data for Lead Product, EB-003

Sep 26, 2024, 8:30 AM EDT - 1 year ago

Enveric Biosciences Presents Data Highlighting Development of EB-003 at European Behavioral Pharmacology Society Biennial Workshop

Lakeland_73 Feb. 23 at 5:57 PM

$ENVB Pathetic volume. Worse price

0 · Reply

EmC_Invests Feb. 23 at 1:25 PM

$ENVB biotech microcap under the radar if buyers return this can move quickly

0 · Reply

__ChartMenace Feb. 23 at 12:41 PM

$ABP $NCEL $NVA $ENVB 6

0 · Reply

HarrisMargin Feb. 23 at 5:35 AM

$ENVB microcap biotech compressing quietly if buyers appear squeeze risk rises

0 · Reply

UgoGreg Feb. 22 at 9:18 PM

$ENVB https://youtu.be/nCPt9XhiRxk

0 · Reply

UgoGreg Feb. 22 at 5:46 PM

$ENVB https://youtu.be/VcWJkTGHJVM

0 · Reply

Luckyjs38 Feb. 21 at 5:02 PM

$ENVB

0 · Reply

Luckyjs38 Feb. 21 at 5:01 PM

$ENVB

0 · Reply

PurplePineApples Feb. 21 at 2:08 AM

$ENVB forming the base let’s see if we can reclaim the 2.30s

0 · Reply

Lakeland_73 Feb. 20 at 9:48 PM

$ENVB 15,000 watchers and 4 posts all day about this trash.

1 · Reply

JackPennies Feb. 20 at 6:53 PM

$ENVB

0 · Reply

JackPennies Feb. 20 at 6:53 PM

$ENVB

0 · Reply

Luckyjs38 Feb. 20 at 3:41 PM

$ENVB they have more cash on hand than their equivalent market cap 🤯🚀

1 · Reply

Luckyjs38 Feb. 20 at 2:34 PM

$ENVB

0 · Reply

Lakeland_73 Feb. 20 at 2:30 PM

$ENVB Pathetic

0 · Reply

Luckyjs38 Feb. 20 at 1:16 PM

$ENVB @Enveric_Bio Cambridge,MA the heart of biopharmaceutical’s with its ground breaking novel drug EB-003 to help cure the epidemic of mental illness around the world one Short selling shill at a time 🤡❤️ Because clowns lives matter too

0 · Reply

24MoneyBags24 Feb. 20 at 11:11 AM

$ENVB buy the dip?

1 · Reply

PennySearch Feb. 20 at 4:30 AM

$ENVB - 24.68x RVOL +8% 17.8M volume (720.8K avg) $1.4M market cap Day Range: 2.23 – 2.47 52W Range: 1.96 – 54.00 $IPST - 14.58x RVOL +9% 4.3M volume (291.7K avg) $8.3M market cap Day Range: 0.70 – 0.94 52W Range: 0.57 – 27.80 $DRMA - 12.91x RVOL +51% 35.7M volume (2.8M avg) $1.3M market cap Day Range: 1.28 – 2.29 52W Range: 1.29 – 23.70 Top gainers with unusually high relative volume. Momentum + attention in one screen. Which one are you watching? 👀 PennySearch

1 · Reply

PennySearch Feb. 20 at 2:45 AM

$ENVB - 24.68x RVOL +8% 17.8M volume (720.8K avg) $1.4M market cap $IPST - 14.58x RVOL +9% 4.3M volume (291.7K avg) $8.3M market cap $DRMA - 12.91x RVOL +51% 35.7M volume (2.8M avg) $1.3M market cap Highest relative volume readings in this morning's scan. Big moves don't start quietly. Which one are you watching? 👀 PennySearch

1 · Reply

cindisilor34 Feb. 19 at 11:04 PM

$ENVB ..

0 · Reply

Lakeland_73 Feb. 19 at 9:44 PM

$ENVB This pile of dog shit is done. I mean they have 5 employees. 🙄

2 · Reply

BATMAN666 Feb. 19 at 8:53 PM

$ENVB

0 · Reply

Market Cap	3.09M
Revenue (ttm)	0.00
Net Income (ttm)	-9.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	99,300
Avg Vol	1,229,706
Day's Range	N/A - N/A
Shares Out	1.39M
Stochastic %K	51%
Beta	0.30
Analysts	Strong Buy
Price Target	$10.00